Cancer Research Versailles No Abst Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Acs, G.
Right arrow Articles by Verma, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Acs, G.
Right arrow Articles by Verma, A.
[Cancer Research 61, 3561-3565, May 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Erythropoietin and Erythropoietin Receptor Expression in Human Cancer1

Geza Acs2, Peter Acs2, Susan M. Beckwith, Richard L. Pitts, Emily Clements, Kondi Wong and Ajay Verma3

Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 [G. A.]; Department of Neurology [P. A., S. M. B., R. L. P., E. C., A. V.] and The United States Military Cancer Institute [A. V.], The Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814; and Department of Neuropathology, Armed Forces Institute of Pathology, Washington, DC 20306 [K. W.]

Erythropoietin (EPO) stimulates the growth of erythroblasts in the bone marrow (C. Lacombe and P. Mayeux, Nephrol. Dial. Transplant., 14 (Suppl. 2): 22–28, 1999). We report basal and hypoxia-stimulated expression of EPO and its receptor, EPOR, in human breast cancer cells, and we demonstrate EPO-stimulated tyrosine phosphorylation and the proliferation of these cells in vitro. In 50 clinical specimens of breast carcinoma, we report high levels of EPO and EPOR associated with malignant cells and tumor vasculature but not with normal breast, benign papilloma, or fibrocystic tissue. Hypoxic tumor regions display the highest levels of EPO and EPOR expression. Enhanced EPO signaling may contribute to the promotion of human cancer by tissue hypoxia.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
G. Paragh, S. M. Kumar, Z. Rakosy, S.-C. Choi, X. Xu, and G. Acs
RNA Interference-Mediated Inhibition of Erythropoietin Receptor Expression Suppresses Tumor Growth and Invasiveness in A2780 Human Ovarian Carcinoma Cells
Am. J. Pathol., April 1, 2009; 174(4): 1504 - 1514.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. O. Arcasoy
Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives
Clin. Cancer Res., August 1, 2008; 14(15): 4685 - 4690.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
C. Bose and K. B. Udupa
Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals
Am J Physiol Cell Physiol, August 1, 2008; 295(2): C394 - C405.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Solar, J. Koval, J. Mikes, J. Kleban, Z. Solarova, J. Lazur, I. Hodorova, P. Fedorocko, and A. J. Sytkowski
Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells
Mol. Cancer Ther., August 1, 2008; 7(8): 2263 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
A. M. Chabowska, M. Sulkowska, A. Chabowski, A. Wincewicz, M. Koda, and S. Sulkowski
Erythropoietin and Erythropoietin Receptor in Colorectal Cancer
International Journal of Surgical Pathology, July 1, 2008; 16(3): 269 - 276.
[Abstract] [PDF]

Home page
 The OncologistHome page
F. Mannello and G. A. M. Tonti
Erythropoietin and Its Receptor in Breast Cancer: Putting Together the Pieces of the Puzzle
Oncologist, July 1, 2008; 13(7): 761 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. A. May and F. R. Khuri
Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion
Cancer Res., June 1, 2008; 68(11): 4013 - 4017.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Saintigny, B. Besse, J.-C. Soria, J.-F. Bernaudin, and P. Callard
Does Erythropoietin Promote Tumor Growth?
Clin. Cancer Res., March 15, 2008; 14(6): 1920 - 1921.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. N. Hamadmad and R. J. Hohl
Erythropoietin Stimulates Cancer Cell Migration and Activates RhoA Protein through a Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase-Dependent Mechanism
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1227 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. L. Bennett, S. M. Silver, B. Djulbegovic, A. T. Samaras, C. A. Blau, K. J. Gleason, S. E. Barnato, K. M. Elverman, D. M. Courtney, J. M. McKoy, et al.
Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
JAMA, February 27, 2008; 299(8): 914 - 924.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
V. Pelekanou, M. Kampa, M. Kafousi, K. Dambaki, K. Darivianaki, T. Vrekoussis, E. Sanidas, D. D. Tsiftsis, E. N. Stathopoulos, and E. Castanas
Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2016 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Saintigny, B. Besse, P. Callard, A.-C. Vergnaud, S. Czernichow, M. Colombat, P. Girard, P. Validire, J.-L. Breau, J.-F. Bernaudin, et al.
Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non Small Cell Lung Cancer
Clin. Cancer Res., August 15, 2007; 13(16): 4825 - 4831.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
C. A. Blau
Erythropoietin in Cancer: Presumption of Innocence?
Stem Cells, August 1, 2007; 25(8): 2094 - 2097.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Kokhaei, A. O. Abdalla, L. Hansson, E. Mikaelsson, M. Kubbies, A. Haselbeck, H. Jernberg-Wiklund, H. Mellstedt, and A. Osterborg
Expression of Erythropoietin Receptor and In vitro Functional Effects of Epoetins in B-Cell Malignancies
Clin. Cancer Res., June 15, 2007; 13(12): 3536 - 3544.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Jelkmann and M. Laugsch
Problems in Identifying Functional Erythropoietin Receptors in Cancer Tissue
J. Clin. Oncol., April 20, 2007; 25(12): 1627 - 1628.
[Full Text] [PDF]

Home page
 Stem CellsHome page
W. M. Brown, P. Maxwell, A. N.J. Graham, A. Yakkundi, E. A. Dunlop, Z. Shi, P. G. Johnston, and T. R.J. Lappin
Erythropoietin Receptor Expression in Non-Small Cell Lung Carcinoma: A Question of Antibody Specificity
Stem Cells, March 1, 2007; 25(3): 718 - 722.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
E. A. Dunlop, A. P. Maxwell, and T. R.J. Lappin
Impaired Downregulation Following Erythropoietin Receptor Activation in Non-Small Cell Lung Carcinoma
Stem Cells, February 1, 2007; 25(2): 380 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Leo, L.-C. Horn, C. Rauscher, B. Hentschel, A. Liebmann, G. Hildebrandt, and M. Hockel
Expression of Erythropoietin and Erythropoietin Receptor in Cervical Cancer and Relationship to Survival, Hypoxia, and Apoptosis
Clin. Cancer Res., December 1, 2006; 12(23): 6894 - 6900.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Henke, D. Mattern, M. Pepe, C. Bezay, C. Weissenberger, M. Werner, and F. Pajonk
Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings?
J. Clin. Oncol., October 10, 2006; 24(29): 4708 - 4713.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Henke, A. Verma, G. Acs, S. Elliott, L. Busse, C. Spahr, and A. M. Sinclair
Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate
Blood, August 1, 2006; 108(3): 1107 - 1109.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, et al.
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
J Natl Cancer Inst, May 17, 2006; 98(10): 708 - 714.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Gewirtz, X. Di, T. D. Walker, and S. T. Sawyer
Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
Clin. Cancer Res., April 1, 2006; 12(7): 2232 - 2238.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Elliott, L. Busse, M. B. Bass, H. Lu, I. Sarosi, A. M. Sinclair, C. Spahr, M. Um, G. Van, and C. G. Begley
Anti-Epo receptor antibodies do not predict Epo receptor expression
Blood, March 1, 2006; 107(5): 1892 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. R. LaMontagne, J. Butler, D. J. Marshall, J. Tullai, Z. Gechtman, C. Hall, A. Meshaw, and F. X. Farrell
Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.
Mol. Cancer Ther., February 1, 2006; 5(2): 347 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. E. Hardee, Z. N. Rabbani, M. O. Arcasoy, J. P. Kirkpatrick, Z. Vujaskovic, M. W. Dewhirst, and K. L. Blackwell
Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.
Mol. Cancer Ther., February 1, 2006; 5(2): 356 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst
Erythropoietin Biology in Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Grote, A. L. Yeilding, R. Castillo, D. Butler, E. Fishkin, D. H. Henry, M. DeLeo, K. Fink, and D. J. Sullivan
Efficacy and Safety Analysis of Epoetin Alfa in Patients With Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
J. Clin. Oncol., December 20, 2005; 23(36): 9377 - 9386.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. D. Lester, M. Jo, W. M. Campana, and S. L. Gonias
Erythropoietin Promotes MCF-7 Breast Cancer Cell Migration by an ERK/Mitogen-activated Protein Kinase-dependent Pathway and Is Primarily Responsible for the Increase in Migration Observed in Hypoxia
J. Biol. Chem., November 25, 2005; 280(47): 39273 - 39277.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. C. Winter, K. A. Shah, L. Campo, H. Turley, R. Leek, R. J. Corbridge, G. J. Cox, and A. L. Harris
Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., November 1, 2005; 11(21): 7614 - 7620.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Engert
Recombinant human erythropoietin in oncology: current status and further developments
Ann. Onc., October 1, 2005; 16(10): 1584 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Leyland-Jones, V. Semiglazov, M. Pawlicki, T. Pienkowski, S. Tjulandin, G. Manikhas, A. Makhson, A. Roth, D. Dodwell, J. Baselga, et al.
Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study
J. Clin. Oncol., September 1, 2005; 23(25): 5960 - 5972.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Tovari, R. Gilly, E. Raso, S. Paku, B. Bereczky, N. Varga, A. Vago, and J. Timar
Recombinant Human Erythropoietin {alpha} Targets Intratumoral Blood Vessels, Improving Chemotherapy in Human Xenograft Models
Cancer Res., August 15, 2005; 65(16): 7186 - 7193.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
Y. Aizawa, N. Nogawa, N. Kosaka, Y. Maeda, T. Watanabe, H. Miyazaki, and T. Kato
Expression of Erythropoietin Receptor-Like Molecule in Xenopus laevis and Erythrocytopenia upon Administration of Its Recombinant Soluble Form
J. Biochem., August 1, 2005; 138(2): 167 - 175.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. W. A. Vogel, F. M. Brouwers, I. A. Lubensky, A. O. Vortmeyer, R. J. Weil, M. M. Walther, E. H. Oldfield, W. M. Linehan, K. Pacak, and Z. Zhuang
Differential Expression of Erythropoietin and Its Receptor in von Hippel-Lindau-Associated and Multiple Endocrine Neoplasia Type 2-Associated Pheochromocytomas
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3747 - 3751.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. C. Leonard, M. Untch, and F. Von Koch
Management of anaemia in patients with breast cancer: role of epoetin
Ann. Onc., May 1, 2005; 16(5): 817 - 824.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Bohlius, S. Langensiepen, G. Schwarzer, J. Seidenfeld, M. Piper, C. Bennett, and A. Engert
Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis
J Natl Cancer Inst, April 6, 2005; 97(7): 489 - 498.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Weiss and L. T. Goodnough
Anemia of Chronic Disease
N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. M. Kumar, G. Acs, D. Fang, M. Herlyn, D. E. Elder, and X. Xu
Functional Erythropoietin Autocrine Loop in Melanoma
Am. J. Pathol., March 1, 2005; 166(3): 823 - 830.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Dagnon, E. Pacary, F. Commo, M. Antoine, M. Bernaudin, J.-F. Bernaudin, and P. Callard
Expression of Erythropoietin and Erythropoietin Receptor in Non-Small Cell Lung Carcinomas
Clin. Cancer Res., February 1, 2005; 11(3): 993 - 999.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. O. Arcasoy, K. Amin, S.-C. Chou, Z. A. Haroon, M. Varia, and J. A. Raleigh
Erythropoietin and Erythropoietin Receptor Expression in Head and Neck Cancer: Relationship to Tumor Hypoxia
Clin. Cancer Res., January 1, 2005; 11(1): 20 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. I. Belenkov, G. Shenouda, E. Rizhevskaya, D. Cournoyer, J.-P. Belzile, L. Souhami, S. Devic, and T. Y.K. Chow
Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin
Mol. Cancer Ther., December 1, 2004; 3(12): 1525 - 1532.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. J. Foster, O. W. Moe, and C. C. W. Hsia
Upregulation of erythropoietin receptor during postnatal and postpneumonectomy lung growth
Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1107 - L1115.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. Tacchini, C. De Ponti, E. Matteucci, R. Follis, and M.A. Desiderio
Hepatocyte growth factor-activated NF-{kappa}B regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines
Carcinogenesis, November 1, 2004; 25(11): 2089 - 2100.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Farrell and A. Lee
The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues
Oncologist, November 1, 2004; 9(suppl_5): 18 - 30.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C.-F. Chou, S. Tohari, S. Brenner, and B. Venkatesh
Erythropoietin gene from a teleost fish, Fugu rubripes
Blood, September 1, 2004; 104(5): 1498 - 1503.
[Abstract] [Full Text] [PDF]

Home page
 NeuroscientistHome page
G. Grasso, A. Sfacteria, A. Cerami, and M. Brines
Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go?
Neuroscientist, April 1, 2004; 10(2): 93 - 98.
[Abstract] [PDF]

Home page
 The OncologistHome page
M. J. Weiss
New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications
Oncologist, December 1, 2003; 8(90003): 18 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
T. G. Eccles, A. Patel, A. Verma, D. Nicholson, Y. Lukes, R. M. Tuttle, and G. L. Francis
Erythropoietin and the Erythropoietin Receptor Are Expressed by Papillary Thyroid Carcinoma fromChildren and Adolescents.: Expression of Erythropoietin Receptor Might Be a Favorable Prognostic Indicator
Ann. Clin. Lab. Sci., October 1, 2003; 33(4): 411 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. L. Blackwell, J. P. Kirkpatrick, S. A. Snyder, G. Broadwater, F. Farrell, L. Jolliffe, D. M. Brizel, and M. W. Dewhirst
Human Recombinant Erythropoietin Significantly Improves Tumor Oxygenation Independent of Its Effects on Hemoglobin
Cancer Res., October 1, 2003; 63(19): 6162 - 6165.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. Acs, P. J. Zhang, C. M. McGrath, P. Acs, J. McBroom, A. Mohyeldin, S. Liu, H. Lu, and A. Verma
Hypoxia-Inducible Erythropoietin Signaling in Squamous Dysplasia and Squamous Cell Carcinoma of the Uterine Cervix and Its Potential Role in Cervical Carcinogenesis and Tumor Progression
Am. J. Pathol., June 1, 2003; 162(6): 1789 - 1806.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Graichen, J. Sandstedt, E. L. K. Goh, O. G. P. Isaksson, J. Tornell, and P. E. Lobie
The Growth Hormone-binding Protein Is a Location-dependent Cytokine Receptor Transcriptional Enhancer
J. Biol. Chem., February 14, 2003; 278(8): 6346 - 6354.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Lappin
The Cellular Biology of Erythropoietin Receptors
Oncologist, February 1, 2003; 8(90001): 15 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Matsuzaki, M. Canis, R. Yokomizo, N. Yaegashi, M. A. Bruhat, and K. Okamura
Expression of erythropoietin and erythropoietin receptor in peritoneal endometriosis
Hum. Reprod., January 1, 2003; 18(1): 152 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
T. R. Lappin, A. P. Maxwell, and P. G. Johnston
EPO's Alter Ego: Erythropoietin Has Multiple Actions
Stem Cells, November 1, 2002; 20(6): 485 - 492.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Stolze, U. Berchner-Pfannschmidt, P. Freitag, C. Wotzlaw, J. Rossler, S. Frede, H. Acker, and J. Fandrey
Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells
Blood, September 18, 2002; 100(7): 2623 - 2628.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Lu, R. A. Forbes, and A. Verma
Hypoxia-inducible Factor 1 Activation by Aerobic Glycolysis Implicates the Warburg Effect in Carcinogenesis
J. Biol. Chem., June 21, 2002; 277(26): 23111 - 23115.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.